A double-blind randomised controlled trial on the effect of Tocovid, a tocotrienol-rich capsule on postoperative atrial fibrillation at the National Heart Institute, Kuala Lumpur: an interim blinded analysis

Table 3 Association between POAF and pre-operative characteristics that were recorded

Pre-operative characteristic	Total*, n (%)	Non-POAF group, n (%)	POAF group, n (%)	p value
Body mass index (kg/m²)	27.23 ± 4.61	27.43 ± 4.55	27.03 ± 5.20	0.50^a
< 18.5	2 (1.29)	1 (50)	1 (50)
18.5–22.9	28 (17.95)	19 (67.90)	9 (32.10)
23–29.9	83 (53.20)	66 (79.50)	17 (20.50)
≥ 30	43 (27.56)	32(74.40)	11 (25.60)
New York heart functional class				0.57^a
NYHA I	58 (53.71)	43 (74.14)	15 (25.86)
NYHA II	48 (44.44)	32 (66.70)	16 (33.30)
NYHA III	2 (1.85)	1 (50)	1 (50)
NYHA IV	0 (0)	(0)	(0)
Left ventricular ejection fraction	46.35 ± 15.82	46.96 ± 15.26	44.87 ± 17.25	0.49^b
Left atrial size (mm)	18.43 ± 5.48	18.11 ± 5.89	19.16 ± 4.43	0.10^c
Right atrial size (mm)	13.83 ± 4.02	13.58 ± 3.99	14.36 ± 4.09	0.14^c

Total n varies slightly for each item due to a small amount of missing data in each
^aTest using Chi Square test
^bTest using independent t test
^cTest using Mann–Whitney test

ISSN: 1749-8090